- Home
- MGN vs ONCO Comparison
MGN vs ONCO Comparison
Compare MGN & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGN | ONCO |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | Malaysia | United States |
| Employees | 4 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MGN | ONCO |
|---|---|---|
| Price | $0.10 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 32.6M | 225.7K |
| Earning Date | 05-12-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $0.09 |
| 52 Week High | $5.18 | $6.73 |
Technical Indicators
Market Signals| Indicator | MGN | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 52.11 |
| Support Level | N/A | $0.64 |
| Resistance Level | $0.16 | $0.94 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 20.29 | 69.17 |
Price Performance
Historical ComparisonAbout MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.